Live
Endpoints NewsADC biotech Ona Therapeutics secures $86.6M in Series B raiseBioPharma DiveA Spanish biotech banks $87M to make differentiated ADCsLonza NewsLonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation - Manufacturing ChemistIlluminaIs Illumina (ILMN) Quietly Solidifying an End‑to‑End Oncology Moat With Deeper DRAGEN Integration? - simplywall.stClinical OMICsCAR T-Cell Therapy Expands Access to Kidney TransplantsEndpoints NewsAlnylam to pay $30M upfront to AI startup Inceptive in RNA R&D dealFierceBiotechLilly, Boehringer to slash at least $1B each from planned investments in GermanyClinical OMICsGenetically Raised Pulse Pressure Predisposes to Dementia-Linked DeathClinical OMICsEngineered Islets Could Eliminate Need for Immunosuppression in Type 1 DiabetesFierceBiotechUnlocking Unstructured Data with AI for Optimized Protocol DevelopmentEndpoints NewsBristol Myers turns focus to AI costs after broad rollout to workers
10x Genomics Blog Feb 27, 2026

Director at 10x Genomics (TXG) sells 7,579 shares under 10b5-1 plan - Stock Titan

Director at 10x Genomics (TXG) sells 7,579 shares under 10b5-1 plan - Stock Titan

Body unavailable. Use the original source.